KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Continuing Operations: 2016-2024

Historic Income from Continuing Operations for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$73.9 million.

  • Amneal Pharmaceuticals' Income from Continuing Operations rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 139.30%. This contributed to the annual value of -$73.9 million for FY2024, which is 51.55% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Income from Continuing Operations of -$73.9 million as of FY2024, which was down 51.55% from -$48.8 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Income from Continuing Operations high stood at $68.6 million for FY2020, and its period low was -$254.8 million during FY2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$73.9 million (2024), whereas its average is -$125.8 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 111.37% in 2020, then crashed by 1,363.65% in 2022.
  • Amneal Pharmaceuticals' Income from Continuing Operations (Yearly) stood at $68.6 million in 2020, then plummeted by 70.61% to $20.2 million in 2021, then slumped by 1,363.65% to -$254.8 million in 2022, then surged by 80.86% to -$48.8 million in 2023, then slumped by 51.55% to -$73.9 million in 2024.